Peripheral blood Th9 cells are a possible pharmacodynamic biomarker of nivolumab treatment efficacy in metastatic melanoma patients
DOI: 10.1080/2162402X.2016.1248327
Akihiko Kitoh,
Atsushi Otsuka,
Chisa Nakashima,
Judith A. Seidel,
Kenji Kabashima,
Megumi Aoki,
Naohito Hatta,
Saeko Nakajima,
Satoshi Fukushima,
Satoshi Koreeda,
Shigeto Matsushita,
Taku Fujimura,
Tatsuya Takenouchi,
Teruki Dainichi,
Tetsuya Honda,
Yu Sawada,
Yumi Nonomura
Keywords: Anti-PD-1 antibody, melanoma, nivolumab, Th9
Abstract:
Full-Text
